source
- FDA releases first updated guidance in 27 years on container and closure systems for drugs and biologicsThe FDA announced a draft guidance that updates the agency’s recommendations for evaluating container and closure systems used in the packaging of new drugs and biologics. This revision is the fir…
- Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety eventRegeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis. The decision…